Credit: Shutterstock photoXencor, a biotech developing antibodies for severe autoimmune/allergic diseases and cancer, postponed its IPO on Thursday, citing poor market conditions. The Monrovia, CA-based company had planned to raise $75 million by offering 10.7 million shares at $7 per share. The postponement comes one day after it slashed its valuation by 41%. The company previously filed to offer 5.0 million shares at a range of $14 to $16. At the revised terms, Xencor would have commanded a market cap of $192 million. Credit Suisse and Leerink Swann were set to be the joint bookrunners on the deal.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
